In the Mexican population with AML, the prevalence of Tet2 mutations is 11.8% and that of DNMT3A mutations is 2.7%, resulting in irregular DNA methylation patterns and changes in the transcriptional expression levels of 16 specific AML-associated genes. This evidence concerns the gene TET2 and acute myeloid leukemia.